Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | PNMT | P11086 | 1/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.40 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 2/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.37 |
| ▸ | TTR | P02766 | 2/20 | 0.37 |
| ▸ | PPARG | P37231 | 1/20 | 0.36 |
| ▸ | PPARA | Q07869 | 1/20 | 0.36 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31634179 | 1.00 | MAPT (0.42) | MAPTMAPK1PNMTTAAR1GRM2 | |
| SCHEMBL29042669 | 0.82 | PNMT (0.47) | MAPTMAPK1PNMTTAAR1GRM2 | |
| SCHEMBL1503218 | 0.81 | PIK3CA (0.45) | MAPTPNMTTAAR1IDO1SLC6A3 | |
| SCHEMBL29489387 | 0.80 | HTT (0.45) | TTR | |
| SCHEMBL1503157 | 0.80 | HTT (0.45) | TTR | |
| SCHEMBL20245287 | 0.79 | MAPT (0.41) | MAPTMAPK1PNMTTAAR1GRM2 | |
| SCHEMBL3746892 | 0.79 | MAPT (0.45) | MAPTMAPK1PNMTTAAR1GRM2 | |
| SCHEMBL2092845 | 0.79 | MAPT (0.41) | MAPTMAPK1PNMTTAAR1GRM2 | |
| SCHEMBL2092848 | 0.79 | MAPT (0.45) | MAPTMAPK1PNMTTAAR1GRM2 | |
| SCHEMBL257064 | 0.79 | TRPA1 (0.41) | MAPTMAPK1PNMTTAAR1GRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11332459-B2 | Benzimidazole derivatives and their uses | TEIJIN PHARMA LIMITED (JP) | 2022-05-17 | — | — | US | disclosed |
| US-20200308145-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USES | AMGEN INC. (US) | 2020-10-01 | — | — | US | disclosed |
| EP-2805954-B1 | 7-SUBSTITUTED HANFANGICHIN B DERIVATIVE, AND PREPARATION METHOD AND USE THEREOF | HANGZHOU BENSHENG PHARMACEUTICAL CO LTD (CN) | 2019-06-19 | — | — | EP | disclosed |
| EP-2805954-B1 | 7-SUBSTITUTED HANFANGICHIN B DERIVATIVE, AND PREPARATION METHOD AND USE THEREOF | HANGZHOU BENSHENG PHARMACEUTICAL CO LTD (CN) | 2019-06-19 | — | — | EP | disclosed |
| US-9328122-B2 | 7-substituted Hanfangichin B derivative, and preparation method and use thereof | HANGZHOU BENSHENG PHARMACEUTICALS CO., LTD. (CN) | 2016-05-03 | — | — | US | disclosed |
| US-9328122-B2 | 7-substituted Hanfangichin B derivative, and preparation method and use thereof | HANGZHOU BENSHENG PHARMACEUTICALS CO., LTD. (CN) | 2016-05-03 | — | — | US | disclosed |
| US-9328122-B2 | 7-substituted Hanfangichin B derivative, and preparation method and use thereof | HANGZHOU BENSHENG PHARMACEUTICALS CO., LTD. (CN) | 2016-05-03 | — | — | US | disclosed |
| US-20140357647-A1 | 7-SUBSTITUTED HANFANGICHIN B DERIVATIVE, AND PREPARATION METHOD AND USE THEREOF | HANGZHOU BENSHENG PHARMACEUTICAL CO., LTD. (CN) | 2014-12-04 | — | — | US | disclosed |
| US-20140357647-A1 | 7-SUBSTITUTED HANFANGICHIN B DERIVATIVE, AND PREPARATION METHOD AND USE THEREOF | HANGZHOU BENSHENG PHARMACEUTICAL CO., LTD. (CN) | 2014-12-04 | — | — | US | disclosed |
| US-20140357647-A1 | 7-SUBSTITUTED HANFANGICHIN B DERIVATIVE, AND PREPARATION METHOD AND USE THEREOF | HANGZHOU BENSHENG PHARMACEUTICAL CO., LTD. (CN) | 2014-12-04 | — | — | US | disclosed |
| EP-1984349-A1 | PIPERIDINE DERIVATIVES AS CXCR3 RECEPTOR ANTAGONISTS | Janssen Pharmaceutica, N.V. (BE) | 2008-10-29 | — | — | EP | disclosed |
| CN-100374440-C | Spirosubstituted piperidines as selective melanin concentrating hormone receptor antagonists for the treatment of obesity | SCHERING CORP (US) | 2008-03-12 | — | — | CN | disclosed |
| WO-2007090826-A1 | PIPERIDINE DERIVATIVES AS CXCR3 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-08-16 | — | — | WO | disclosed |
| US-20060063782-A1 | 3-Hetero arylmethoxy ! pyridines and their analogues as p38 map kinase inhibitors | ASTEX THERAPEUTICS LIMITED (GB) | 2006-03-23 | — | — | US | disclosed |
| CN-1665812-A | Spirosubstituted piperidines as selective melanin concentrating hormone receptor antagonists for the treatment of obesity | SCHERING CORP (US) | 2005-09-07 | — | — | CN | disclosed |
| EP-1545523-A1 | 3-&-grave;(HETERO) ARYLMETHOXY ! PYRIDINES AND THEIR ANALOGUES ASP38 MAP KINASE INHIBITORS | Astex Technology Limited (GB) | 2005-06-29 | — | — | EP | disclosed |
| WO-2005002673-A1 | RAF KINASE INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2005-01-13 | — | — | WO | disclosed |
| WO-2004004720-A1 | 3-`(HETERO) ARYLMETHOXY ! PYRIDINES AND THEIR ANALOGUES AS P38 MAP KINASE INHIBITORS | ASTEX TECHNOLOGY LIMITED (GB) | 2004-01-15 | — | — | WO | disclosed |
| CN-1099030-A | Biocidal compounds | SHELL INT RESEARCH (NL) | 1995-02-22 | — | — | CN | disclosed |
| EP-0623601-A1 | N-(3-Fluorobenzyl)heterocyclic derivatives and their use as pesticides | SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) | 1994-11-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060063782-A1 | 3-Hetero arylmethoxy ! pyridines and their analogues as p38 map kinase inhibitors | MAPK1, MAPK3, MAPK10 | MAPT 2630/4885MAPK1 1/4885PNMT 1640/4885 |
| US-20200308145-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USES | TRPC6, TRPV6, TRPM6 | MAPT 3674/4885MAPK1 2222/4885PNMT 3338/4885 |
| US-20140357647-A1 | 7-SUBSTITUTED HANFANGICHIN B DERIVATIVE, AND PREPARATION METHOD AND USE THEREOF | UGT2B7, CYP3A7, UGT1A7 | MAPT 4497/4885MAPK1 1302/4885PNMT 688/4885 |
| US-11332459-B2 | Benzimidazole derivatives and their uses | TRPC6, TRPV6, TRPM6 | MAPT 3674/4885MAPK1 2222/4885PNMT 3338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.